INTRODUCTION

Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenerative human prion disease. Based on its cause, CJD can be classified as sporadic, iatrogenic, familial, or variable. Most CJD cases (85%) are sporadic, while 10%–15% of cases are familial, and a minority are iatrogenic. The onset of sporadic CJD (sCJD) usually occurs in the seventh decade of life, with a median time to death of 5 months and with 80% of patients dying within 1 year.  

CASE REPORT

A 70-year-old woman with right hemiplegia visited the hospital on the day of onset. She had not experienced any neurological abnormalities before this presentation and had no medical or family history of brain disease. She was a non-smoker, her blood sugar level was normal, and her serum lipid levels were high (total cholesterol, 273 mg/dL; low-density lipoprotein, 184 mg/dL). She was alert, and her cognitive status was good. Her Korean version of the Mini-Mental State Examination score was high (K-MMSE = 27), with only three points less than a full score in the attention and calculation category. Her right upper and lower extremity muscle strength measured using the Medical Research Council (MRC) scale was 4/4. No abnormalities were identified on laboratory studies, including those of complete blood count, serum electrolytes, liver function, and renal function on the day of admission. Brain DWI showed hyperintense signals in the left frontal and temporal lobe areas (Fig. 1A). Based on hemiplegic symptoms and...
corresponding brain imaging results, the patient was diagnosed with cerebral infarction and treatment with aspirin, clopidogrel, and atorvastatin was initiated. Until the 12th day of hospitalization, the patient’s symptoms did not worsen or disappear, although her muscle strength remained weakened.

On the 12th day of hospitalization, the patient’s level of consciousness temporarily changed to drowsy and her right upper and lower extremity muscle strength measured using the MRC scale deteriorated by 1/2. Brain DWI revealed additional hyperintense signals in the left frontal and temporal lobes and both basal ganglia areas, which led to a diagnosis of recurrent cerebral infarction and continued treatment for stroke (Fig. 1B).

On the 18th day of hospitalization, the patient developed Broca’s aphasia. Her cognition deteriorated, and myoclonus appeared in her right upper and left lower extremities. Her scores for memory recall, calculation, and orientation in K-MMSE dropped, with her overall score also lower than the previous results scores (K-MMSE score = 20). Repeated brain DWI confirmed that the hyperintense signals extended to both the cortex and caudate nucleus and putamen on brain DWI. Therefore, she was strongly suspected of having CJD and was transferred to another university hospital for accurate diagnostic assessment.

Western blot analysis detected 14-3-3 proteins in her cerebrospinal fluid; real-time quaking-induced conversion assays also detected the scrapie isoform of the prion protein in the cerebrospinal fluid. The possibility of familial CJD was ruled out as no genetic mutations associated with CJD were found in the prion genetic test and she had no family history of CJD. The possibility of iatrogenic CJD was also excluded because she had no medical history of neurosurgical treatment, surgery, or other body tissue transplant at risk of transmission of prion proteins. Thus, the patient was diagnosed with sCJD. The informed consent was waived.

**DISCUSSION**

The most common early symptom of sCJD is cognitive impairment, and other symptoms such as cerebellar, constitutional, behavioral, sensory, motor, and visual symptoms may also appear. The symptoms of sCJD can vary and appear in unusual patterns; thus, this condition may be easily mistaken for other central nervous system disorders. Therefore, the best approach in suspected cases of sCJD is to consider patient care with a critical appraisal of the information known about the disease. The diagnostic criteria for sCJD are outlined in Table 1. While the clinical features of sCJD can be diverse, acute onset and stepwise deterioration of the pyramidal symptoms resembling the clinical course of a recurrent stroke are rare. However, cerebrovascular diseases usually worsen in a stepwise pattern; thus, it is rare to see a gradual deterioration of symptoms over several hours or days. A previous study reported a case in Korea in which hemiplegia occurred as an initial symptom, with corresponding brain magnetic resonance imaging (MRI) results, after which the patient was diagnosed with sCJD. The case exhibited progressive deterioration of symptoms; the typical symptoms of sCJD such as rigidity, bradykinesia, and tremor appeared 8 days later, which enabled the early suspicion of sCJD. Another case was reported in which atypical white matter lesions were observed on brain MRI, but the...
initial symptoms were typical of sCJD.8) Another case in Germany described a patient with hemiplegia and corresponding brain MRI findings. This case showed symptoms of cognitive decline before hemiplegia onset, followed by rapid cognitive deterioration. The patient further showed deterioration of symptoms such as dystonic-hyperkinetic movement and myoclonus, which are symptoms of sCJD.9) Such cases attained a relatively early diagnosis of sCJD as the symptoms had a gradual progressive onset and did not resemble the clinical course of a recurrent stroke.

The patient in the present report had cerebrovascular risk factors such as hypercholesterolemia, old age, and menopause. She also presented with hemiplegia and corresponding high-intensity signals on brain MRI; moreover, her symptoms had acute onset and deteriorated in a stepwise pattern. Furthermore, the changes identified on brain MRI corresponded to those for stroke, leading to a diagnosis of recurrent stroke. Consequently, antiplatelet therapy continued until the typical symptoms of sCJD appeared. The clinical course and imaging results of this case, which resembled those of recurrent stroke, demonstrated the variability of sCJD symptoms. Therefore, it is crucial to understand the potential for uncommon clinical outcomes of sCJD to avoid unnecessary testing and treatment.

ACKNOWLEDGMENTS

CONFLICT OF INTEREST

The researchers claim no conflicts of interest.

FUNDING

None.

Table 1. Diagnostic criteria for sCJD

| Type | Criteria |
|------|----------|
| A    | Rapidly progressive dementia |
| B    | Myoclonus |
|      | Visual or cerebellar signs |
|      | Pyramidal/extrapyramidal signs |
|      | Akinetic mutism |
| C    | Periodic sharp and wave complex on EEG during an illness of any duration |
|      | Positive 14-3-3 cerebrospinal fluid assay and a clinical duration to death of < 2 years |
|      | MRI high-intensity signal abnormalities in the caudate nucleus and/or putamen on diffusion-weighted or FLAIR imaging |
| D    | Routine investigations that do not indicate an alternative diagnosis |
| E    | Duration < 2 years |

sCJD, sporadic Creutzfeld-Jacob disease; EEG, electroencephalography; MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery.

Possible CJD = “A” + at least two of “B” + absent “C” + “E.”
Probable CJD = “A” + at least two of “B” + at least one of “C” + “D.”
Definite CJD = diagnosed using standard neuropathological techniques and/or immunocytochemical analyses; and/or western blot confirmed protease-resistant prion protein and/or the presence of scrapie-associated fibrils.

AUTHOR CONTRIBUTIONS

Conceptualization, MJB; Data curation, MJB; Methodology, MJB, YRH; Project administration, MJB, YRH; Supervision, KHH; Writing—original draft, MJB, IHK; Writing—review & editing, MJB, KHH.

REFERENCES

1. Terrin A, Barp A, Zanusso G, Gallo P, Cagnin A. Sporadic Creutzfeldt-Jakob disease presenting with isolated progressive non-fluent aphasia in a young woman. Neurol Sci 2017;38: 1535-7.
2. Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004.
3. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus 2015;39:E2.
4. Rabinovici GD, Wang PN, Levin J, Cook L, Pravdin M, Davis J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 2006;66:286-7.
5. Cambier DM, Kantarci K, Worrell GA, Westmoreland BF, Aksamit AJ. Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. Clin Neurophysiol 2003;114:1724-8.
6. World Health Organization. Global surveillance, diagnosis, and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation [Internet]. Geneva, Switzerland: World Health Organization; 1998 [cited 2021 May 17]. Avail-
7. Cho GN, Jeong HY, Noh SW, Lee SY, Kim YJ, Kim SJ. Creutzfeldt-jakob disease mimicking a stroke as initial manifestation. J Korean Neurol Assoc 2012;30:374-6.
8. Lee HS, Park HY, Chang H. White matter lesions in a patient with Creutzfeldt-Jakob Disease. J Korean Geriatr Soc 2013;17:259-62.
9. Szabo K, Achtnichts L, Grips E, Binder J, Gerigk L, Hennerici M, et al. Stroke-like presentation in a case of Creutzfeldt-Jakob disease. Cerebrovasc Dis 2004;18:251-3.